I think the recommendation in the Romanow report was that eventually, the review part of your mandate would include generic drugs. That was the intent, eventually. At the moment, you're just reporting, but eventually you would be able to give an opinion based on international examples about whether, for this huge amount of our public dollars that are going to generic drugs, we're paying too much for them.
On March 28th, 2007. See this statement in context.